Activated Charcoal Anamirta Cocculus Seed Arbutus
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Activated Charcoal Anamirta Cocculus Seed Arbutus
- Multi-Ingredient Homeopathic Complex: Insufficient Data for Repurposing Analysis
Multi-Ingredient Homeopathic Complex: Insufficient Data for Repurposing Analysis
One-Sentence Summary
This Evidence Pack describes a 19-ingredient complex product consisting primarily of homeopathic and botanical components (including Arnica montana, Echinacea, Lycopodium, Phosphorus, Tellurium, and Toxicodendron), alongside pharmacologically active substances at unspecified concentrations (Arsenic Trioxide, Epinephrine). The TxGNN model returned no predicted indications for this compound, as the multi-ingredient mixture could not be matched to a single DrugBank entity. With 0 clinical trials and 0 publications identified for the combination as a whole, this candidate cannot proceed to evidence-based repurposing evaluation at this time.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | None on record |
| Predicted New Indication | None (TxGNN returned no predictions) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction only, but no prediction was generated |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No prediction was generated by TxGNN for this candidate, so a mechanism-based justification cannot be constructed.
The compound contains 19 listed components spanning three distinct categories:
- Classical homeopathic dilutions: Anamirta cocculus seed, Arbutus andrachne leafy shoot, Arnica montana, Canis lupus familiaris milk, Kalmia latifolia leaf, Lycopodium clavatum spore, Phosphorus, Rhododendron tomentosum leafy twig, Sus scrofa thyroid, Tellurium, Toxicodendron pubescens leaf
- Botanical/herbal extracts: Echinacea angustifolia, Glycyrrhiza glabra (licorice), Goldenseal (Hydrastis canadensis), Taraxacum officinale (dandelion), Trifolium pratense flower (red clover), Activated Charcoal
- Pharmacologically active substances at unspecified concentrations: Arsenic Trioxide, Epinephrine
Because the TxGNN knowledge graph operates on single DrugBank-mapped chemical entities, a 19-ingredient mixture of this heterogeneity cannot be assigned a unified mechanism of action, and the model returned zero candidates. Each ingredient would need to be evaluated independently before any repurposing rationale could be constructed.
Clinical Trial Evidence
Currently no related clinical trials registered for this multi-ingredient combination.
Literature Evidence
Currently no related literature available for this multi-ingredient combination as a unified drug entity.
US Market Information
This product has no US NDA approvals on record.
Safety Considerations
Please refer to the package insert for safety information.
Note: Two components in this mixture warrant independent pharmacovigilance attention regardless of overall product status:
- Arsenic Trioxide — a known cytotoxic agent with cardiotoxicity (QT prolongation) and myelosuppression risk at therapeutic doses; context-dependent on concentration.
- Epinephrine — a potent sympathomimetic with cardiovascular and anaphylaxis-reversal indications; concentration and route-dependent risk profile.
No drug interaction data was identified for the combination as a whole (DDI query: not found).
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN model produced no repurposing predictions for this multi-ingredient compound because it could not be resolved to a single DrugBank entity; without a prediction, there is no repurposing hypothesis to evaluate, and no clinical or literature evidence was identified for the combination.
To proceed, the following is needed:
- Ingredient-level decomposition: Evaluate each of the 19 components individually through TxGNN using their respective DrugBank IDs (e.g., Arsenic Trioxide → DB01169; Epinephrine → DB00668) before any combination analysis is attempted.
- Concentration and formulation data: Determine whether this is a homeopathic dilution product (e.g., 6C, 30C) or a standardized botanical extract; homeopathic dilutions beyond Avogadro’s limit are not pharmacologically evaluable by standard models.
- Regulatory classification: Clarify whether this product is classified as a homeopathic drug, dietary supplement, or conventional pharmaceutical — this determines which evidence framework applies.
- MOA documentation: Source mechanism-of-action data from DrugBank for any pharmacologically active components before machine-learning-based repurposing is attempted.
- TFDA package insert: Retrieve warning and contraindication text to enable S1 safety screening (currently Blocking data gap DG001).
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.